An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

PHASE3CompletedINTERVENTIONAL

Enrollment

258

Participants

Timeline

Start Date

July 29, 2016

Primary Completion Date

August 15, 2017

Study Completion Date

August 15, 2017

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG

OTX-101 0.09%

0.09% cyclosporine nanomicellar solution

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT02845674 - An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca | Biotech Hunter | Biotech Hunter